James Mason, MD
- Hematology and Oncology
- Medical Oncology
Accepts new patientsExpertise
Hospital Affiliations
Languages
- English
Biography
James Mason, MD, is a hematologist and oncologist who has been in practice for over 26 years. Dr. Mason has a special interest in blood and bone marrow transplantation. He believes in taking a collaborative approach to medicine, and is part of a large, integrated system of physicians, nurses, pharmacists and specialists — all dedicated to providing excellent patient care.
In addition to his experience with therapy programs for breast cancer and certain solid tumors, Dr. Mason performs blood and marrow stem cell transplantation for patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, acute and chronic leukemia and other diseases of the blood and bone marrow. His research focus is on acute leukemias and computational biology.
Dr. Mason, a San Diego native, is director of the Scripps Blood and Marrow Transplant (BMT) Program and the stem cell lab at Scripps Clinic Torrey Pines. Under his leadership, the BMT Program offers innovative care — incorporating dose-intensive chemotherapy and/or immunotherapy — and is recognized as a leader in the BMT field on the West Coast.
Board Certifications
Medical Education
Internships
Residencies
Fellowships
Publications
- Most Recent
- Alphabetical
- Oldest First
Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing.
Novak ER, Deshpande A, Finlay D, Mason JR, Deshpande AJ, Adams PD, Li S
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.
Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, Garcia-Romero MT, Lopez-Santiago NC, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran JM, Fathi AT, Hall A, Jacoby MA, Lancet JE, Mannis GN, Stein AS, Mims AS, Rizzieri D, Olin RL, Perl AE, Schiller GJ, Shami PJ, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman ML, Roboz GJ, Khoury JD, Qazilbash MH, Aung P, Cuglievan B, Madanat YF, Kharfan-Dabaja MA, Pawlowska AB, Taylor J, Tallman MS, Dhakal P, Lane AA
An observational study of hospitalized COVID-19 patients with cancer in San Diego county.
Hermel DJ, Cham J, Spierling Bagsic SR, Hong LK, Costantini CL, Mason JR, Saven A, Sigal DS
The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.
Khateb A, Deshpande A, Feng Y, Finlay D, Lee JS, Lazar I, Fabre B, Li Y, Fujita Y, Zhang T, Yin J, Pass I, Livneh I, Jeremias I, Burian C, Mason JR, Almog R, Horesh N, Ofran Y, Brown K, Vuori K, Jackson M, Ruppin E, Deshpande AJ, Ronai ZA
ABO phenotype and clinical correlates of COVID-19 severity in hospitalized patients.
Hermel DJ, Spierling Bagsic SR, Costantini CL, Mason JR, Gahvari ZJ, Saven A
World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians.
Abraham GM, Obley AJ, Humphrey LL, Qaseem A, Scientific Medical Policy Committee of the American College of Physicians, Centor RM, Akl E, Forceia MA, Haeme R, Hamilton PG, Hood GA, Jokela JA, Kansagara DL, Levine MA, Mason JR, Marcucci M
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI
Effects of long-term cryopreservation on peripheral blood progenitor cells.
Vosganian GS, Waalen J, Kim K, Jhatakia S, Schram E, Lee T, Riddell D, Mason JR
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation.
Sala-Torra O, Hanna C, Loken MR, Flowers ME, Maris M, Ladne PA, Mason JR, Senitzer D, Rodriguez R, Forman SJ, Deeg HJ, Radich JP
If you see an error or omission on a provider’s profile page, please contact us.